Mustang Bio (MBIO) Gains from Investment Securities (2016)
Mustang Bio (MBIO) posted quarterly Gains from Investment Securities of $161000.0 for Q4 2016, up 8150.0% quarter-over-quarter from -$2000.0 in Q3 2016.
Mustang Bio (MBIO) Gains from Investment Securities (2016) Analysis & Trends
Mustang Bio (MBIO) has reported Gains from Investment Securities for 1 consecutive years, with $161000.0 the latest figure, recorded in Q4 2016.
- In Q4 2016, Gains from Investment Securities changed N/A year-over-year to $161000.0; the TTM figure through Dec 2017 stood at $159000.0 (changed N/A YoY), while the FY2016 annual figure was $159000.0, changed N/A from the prior year.
- Gains from Investment Securities climbed to $161000.0 in Q4 2016 per MBIO's latest filing, from -$2000.0 in the prior quarter.
- Across five years, Gains from Investment Securities topped out at $161000.0 in Q4 2016 and bottomed at -$2000.0 in Q3 2016.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Mustang Bio | 3.90 Mn | 3.90 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2016 | 161,000.00 |
| Dec 31, 2016 | 161,000.00 |
| Sep 30, 2016 | -2,000.00 |
| Sep 30, 2016 | -2,000.00 |